ABSTRACT -The outcome of antidepressant treatment for depressive symptoms and cognitive impairm e n t at the acute phase of stroke is controversial. We investigated 93 patients, treating with citalopram 36 with s e v e re depressive symptoms (HAM-D: Hamilton Depression Rating Scale ≥18), whilst 19 patients with mild d e p ressive symptoms, and 38 non-depressed patients, remained untreated. At baseline (two weeks after s t roke), patients with severe depressive symptoms had lower scores in total Dementia Rating Scale (DRS) and in the attention and memory DRS subscales, than the non-depressed patients (p≤0.001). At the end of the three-month follow-up period, these diff e rences had disappeared, but patients initially with mild d e p ressive symptoms had higher HAM-D scores than the non-depressed patients (p=0.015), and lower s c o res in DRS attention and memory subscales (p<0.01), than the patients treated with citalopram. Tre a t m e n t was associated with improved mood, memory and attention, and a placebo-controlled study on the tre a tment of mild depressive symptoms is warranted.
D e p ressive symptoms are frequent after stro k e and post-stroke depression is associated with excess d i s a b i l i t y, cognitive impairment, and mort a l i t y 1 , 2 . Treatment of post-stroke depression improves mood, but it is still unsettled whether the use of antidepre ssants may improve cognition or re c o v e ry after stro k e 3 . P o s t -s t roke depression has been diagnosed either in the acute as in the chronic phase after stroke, and some of the diff e rences between the results of studies may be due to grouping together two pro b a b l y d i ff e rent conditions 2 . Diagnosis of depression in the acute phase of stroke may be very difficult because symptoms that are associated with depression such as apathy, lack of interest or pleasure in activities, and even crying may be either attributed to stro k e or to depression in the first days or weeks following a stroke 2 . The optimal start point for treatment of depressive symptoms after stroke has yet to be established. In a double-blind, placebo-controlled study, the eff e c t of fluoxetine could not be ascertained within the first t h ree months after stroke because spontaneous rec o v e ry masked any possible benefits of antidepre ssant tre a t m e n t 4 . Post-stroke cognitive impairment is also very common, where its cause is probably multi-factorial 5 . The role of mood changes in the genesis of post-stroke cognitive impairment remains controversial 6, 7 , and there is also controversy regarding the outcome of cognitive impairment following mood impro v e m e n t 6 , 8 . A recent systematic review of p h a rmacological therapies of depression after stro k e concluded that there is no evidence of benefit of ant i d e p ressants in improving cognitive function 3 . Most of the studies have analyzed the effects of the tre a tment for depression based on the general intellectual function only, without focusing on specific cognitive domains [6] [7] [8] [9] . The aim of this study was to investigate the outcome of both depressive symptoms and cognitive i m p a i rment following antidepressant treatment in the acute phase of ischemic stroke, seeking to identify the cognitive domains most improved by the treatment.
METHOD
F rom 18 January 1998 to 30 July 2000, 171 patients with acute supratentorial ischemic stroke who had been consecutively admitted to the Emergency Room of the Catholic University of São Paulo Hospital, in Sorocaba, São Paulo State, Brazil, were evaluated for inclusion in the study. After evaluation, and according to inclusion and exclusion criteria, 73 patients were excluded from the study (aphasia that p recluded neuropsychological evaluation : 21; absence of evidence of stroke on CT-scan: 17; previous stroke based on information or in CT-scan: 14; Glasgow scale under 13: 12; transient ischemic attack (TIA): 8; Binswanger disease: 1). Another five patients refused to participate; giving a final sample comprising 93 patients.
The patients were examined on the day after admission to the hospital (visit 1), 14 days later (visit 2: baseline), and subsequently after 30 (visit 3), 60 (visit 4) and 90 (visit 5) days.
Cognitive impairment was assessed with the Mattis Dementia Rating Scale (DRS) 1 0 , 1 1 by a psychologist blind to the clinical data. The severity of the depressive symptoms was measured by the psychologist using the 21-item Hamilton Rating Scale for Depression (HAM-D) 1 2 . CT-scans were perf o rmed between day 3 and day 7, and were analyzed by the same neuroradiologist, who did not have access to the clinical assessments. Localization and volume of the lesions were estimated using an atlas of the human brain 13 . At baseline, the patients were classified into those with s e v e re depressive symptoms (HAM-D ≥18; N=36), with mild d e p ressive symptoms (HAM-D scores 13-17; N=19) and nondepressed patients (HAM-D scores < 13; N=38).
Patients with severe depressive symptoms were tre a ted with citalopram10 mg per day starting after baseline. This dose was increased to 20 mg per day after 10 days. The dose was kept at 20 mg per day, or was increased to 40 mg per day if HAM-D ≥18 on visit 3. Both patients with mild d e p ressive symptoms and non-depressed patients were not treated with citalopram. I n f o rm ed consent was obtained from all subjects and/or their relatives. The study was approved by the Ethics Committee of Catholic University of São Paulo.
Statistical analysis were perf o rmed using the chi-square test for categorical variables and analysis of variance with a fixed value (F) for quantitative variables. Diff e rences between groups and visits were evaluated using multiple comparison tests with the Bonferroni method. The last observation carried forw a rd (LOCF) method was used when nece s s a ry. SPSS for Windows, version 10.0 (SPSS Inc.), was used for the statistical analysis. The value of significance accepted was 0.05.
RESULTS
Ages of the patients with severe depressive symptoms (65.8±10.4; range 44-86), mild depressive symptoms (63.7±12.8; range 40-82), and non-depre s s e d patients (63.5±14.1; range 37-90) did not differ (p= 0.699). Other characteristics are shown in Table 1 .
Lesions were larger in the patients with severe d e p ressive symptoms, more often being subcort i c a l and anterior, than in the other two groups. The side of the hemispheric lesion was not diff e rent in the three groups (Table 2) .
During the follow-up, two patients with mild dep ressive symptoms at baseline had deteriorated to s e v e re depressive symptoms by visit 3, and were tre a ted with citalopram. Two patients died during the follow-up, one of them belonging to the group tre a ted with citalopram, whilst there were two dro p o u t s (also one in the citalopram group). Two additional patients, not treated with citalopram, had myocardial infarction and stroke re s p e c t i v e l y. For the analysis of the outcome, the results of the observations at baseline of these eight patients were carried forw a rd.
The three groups manifested diff e rent evolutions f rom visits 2 to 5 in HAM-D (F=16.49; p<0.001) and in DRS total scores (F=7.32; p<0.001), as well as in DRS attention (F=9.70; p< 0.001), memory (F=10.84; p< 0.001) and in initiation-perseveration subscale score s (F=2.96; p=0.009). On all these scales and subscales, the percentages of variation of scores between visits 2 and 5 were higher in patients with severe depre ssive symptoms. However, the evolutions of the thre e g roups were not diff e rent for construction and conceptualization subscale scores.
Mean scores at baseline, and at the end of the follow-up are shown in Table 3 and in the Figure. In HAM-D, each group differed from one another at baseline (p<0.001), whilst at visit 5, only the patients with mild depressive symptoms differed from the non-depressed patients (p=0.015).
At baseline, the mean scores of the patients with s e v e re depressive symptoms diff e red from those of the non-depressed patients on total DRS (p=0.001), and in the attention (p<0.001), memory (p=0.001) and initiation-perseveration (p=0.003) DRS subscales. At visit 5, these differences were no longer present, but the group of patients with mild depressive symptoms showed lower mean scores in the attention DRS subscale when compared to both the non-depre s s e d (p=0.001), and citalopram-treated patients (p<0.001), along with lower mean scores in the memory DRS subscale when compared to the citalopram-tre a t e d patients (p=0.003), and a trend toward lower mean score in total DRS when compared to both the nond e p ressed (0.097) and citalopram-treated patients (p=0.098).
F i g u re. Mean scores of the three groups of patients: (A) in the Hamilton Rating Scale for Depression (Ham-D), (B) in the total Dementia Rating Scale (DRS) and (C) in the attention and (D) memory subscales of DRS
during the follow-up. 
DISCUSSION
Treatment with antidepressant was associated with improvement of both mood and cognition in this study. The cognitive improvement observed in the patients treated with citalopram in the acute phase of stroke strengthens the hypothesis that mood changes play a significant role in cognitive impairment after stroke, but also that its origin is multifactorial, given that after improvement of depre s s i v e symptoms, mean DRS scores still remained low. The low mean scores of the cognitive tests in this study a re also related to the low educational level of our patients.
Although it is conceivable depressive symptoms and cognitive impairment might have improved spontaneously without treatment after the acute phase of the stroke, the evolution shown by our patients with mild depressive symptoms suggests this would not have been the case. Mean HAM-D scores for this g roup decreased spontaneously, but not to the same extent as the treated group, and at the end of the follow-up, scores were higher than those of the nond e p ressed patients. Besides, it is noteworthy that at the end of follow-up, the patients with mild depre ssive symptoms had lower mean scores in the attention and memory DRS subscales when compared to the patients who had been treated with antidepre ssant.
Citalopram was the chosen antidepressant agent because this selective serotonin reuptake inhibitor has a favorable profile of side effects, and because it had shown good results in a previous study 1 4 . In other recent studies, citalopram has shown good eff icacy and lack of severe side effects in the tre a t m e n t of post-stroke depression 15, 16 .
We have described our patients as having "depre ssive symptoms", and have endeavored to avoid the use of the word "depression", because it is very difficult or even impossible, to rely on standard criteria for depression such as the DSM-IV 1 7 , in the acute phase of stroke 2 .
It should be noted that the mean score of the g roup classified as having severe depressive symptoms (21.0±2.2) was not as high as the scores observ e d in endogenous major depression, or even in depre ssion in the non-acute phase of stro k e 1 8 , 1 9 . However, only about 40% of our patients were considered nond e p ressed according to HAM-D scores, showing that mood changes are very common in the acute phase of stroke, albeit not very severe, as previously described in other studies 2 0 , 2 1 . Another factor that may have contributed to the high frequency of depre ssive symptoms in these patients is low education, which may be associated with a higher pre v a l e n c e of depressive symptoms 22, 23 .
S e v e re depressive symptoms were associated with l a rg e r, more frequently subcortical and anterior ischemic lesions in this study, in line with several 2 4 , 2 5 , but not all re p o rts of post-stroke depre s s i o n 2 6 . On the other hand, it was not associated with the side of the hemispheric lesion. The importance of the side of the lesion for the occurrence of post-stroke depre ssion has yet to be ascert a i n e d 2 7 . It is important to note that we excluded 21 patients with aphasia, which may have had an influence on our results concerning the importance of the side of the lesion.
This study has several limitations. Magnetic re s onance imaging, particularly if including the diff u s i o n method, would have had more sensitivity and specificity for the diagnosis of acute stroke and for the topographic correlation, than the CT-scan we used 2 8 . The low educational level of most of our patients may is another limitation, indicating the need to confirm these data for other populations. The most important limitation however, is the lack of a placebo a rm. However, when designing the study we conside red that it would be unethical to withhold the tre a tment for patients with severe depressive symptoms.
To conclude, our data suggest that treatment of d e p ressive symptoms in the acute phase of stro k e i m p roves both mood and cognition and also indicate that a double-blind placebo-controlled study on the t reatment of mild depressive symptoms in the acute phase of stroke is warranted.
